Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 16/20 | 0.83 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923546 | 0.91 | PTGER1 (1.00) | PTGER1 | |
| SCHEMBL4777194 | 0.91 | PTGER1 (0.80) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL14008082 | 0.91 | PTGER1 (0.69) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL4774733 | 0.91 | PTGER1 (0.80) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL14008092 | 0.90 | PTGER1 (0.68) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL14008078 | 0.88 | PTGER1 (0.66) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL14008090 | 0.88 | PTGER1 (0.66) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL4923050 | 0.87 | PTGER1 (0.74) | PTGER1 | |
| SCHEMBL14008089 | 0.87 | PTGER1 (0.64) | PTGER1NPC1POLBRAB9AMRGPRX4 | |
| SCHEMBL4915784 | 0.87 | PTGER1 (0.74) | PTGER1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| EP-1874749-A1 | FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114272-A1 | FURAN COMPOUNDS USEFUL AS EPl RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287430-A1 | Furan Compounds Useful As Ep1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885NPC1 3010/4885POLB 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.